Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.
On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.
Professor & Program Chair
Maria Luisa Pineda
Co-Founder & CEO
Co-Founder & CTO
Associate Research Professor
Professor & Director
Microsoft Announces Winners of AI Startup Competition
Platform Targeting Genetic Cause of SMA and Like Diseases Supported by $1.5M NIH Grant
Thiel's Breakout Labs backs Envisagenics
Documentaries, videos and podcasts
- Breakout LabsBreakout Labs is a grant making body of the Thiel Foundation supporting the commercialization of scientific products and services located in San Francisco, California.
- RNARNA stands for ribonucleic acid. Messenger RNA (mRNA) is copied or transcribed from DNA and carries the coding information for the generation of a protein encoded by a gene. Different types of non-coding RNAs have roles in converting mRNA into protein and perform other regulatory functions in the cell.
- Artificial intelligenceArtificial intelligence (AI) is intelligence exhibited by machines.